Movatterモバイル変換


[0]ホーム

URL:


US20090175953A1 - Nanodispersions - Google Patents

Nanodispersions
Download PDF

Info

Publication number
US20090175953A1
US20090175953A1US12/309,306US30930607AUS2009175953A1US 20090175953 A1US20090175953 A1US 20090175953A1US 30930607 AUS30930607 AUS 30930607AUS 2009175953 A1US2009175953 A1US 2009175953A1
Authority
US
United States
Prior art keywords
soluble
solvent
water
payload
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/309,306
Inventor
Doris Angus
David John Duncalf
Andrew James Elphick
Alison Jayne Foster
James Long
Steven Paul Rannard
Dong Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iota Nanosolutions Ltd
Original Assignee
Conopco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conopco IncfiledCriticalConopco Inc
Assigned to CONOPCO, INC. D/B/A UNILEVERreassignmentCONOPCO, INC. D/B/A UNILEVERASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: ANGUS, DORIS, DUNCALF, DAVID JOHN, ELPHICK, ANDREW JAMES, FOSTER, ALISON JAYNE, LONG, JAMES, RANNARD, STEVEN PAUL, WANG, DONG
Publication of US20090175953A1publicationCriticalpatent/US20090175953A1/en
Assigned to IOTA NANOSOLUTIONS LIMITEDreassignmentIOTA NANOSOLUTIONS LIMITEDASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: CONOPCO, INC. D/B/A UNILEVER
Assigned to IOTA NANOSOLUTIONS LIMITEDreassignmentIOTA NANOSOLUTIONS LIMITEDASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: CONOPCO, INC. D/B/A UNILEVER
Abandonedlegal-statusCriticalCurrent

Links

Classifications

Definitions

Landscapes

Abstract

The invention provides process for making contra-soluble nano-dispersions of at most sparingly-soluble materials in a soluble carrier material comprising the steps of: (i) providing a single phase mixture of: a) a solvent or a mixture of miscible solvents, b) at least one carrier material soluble in solvent (a), said carrier material being also contra-soluble to payload material (c) and solid at ambient temperature, c) at least one a payload material which is soluble in solvent (a), and, (ii) drying the mixture to remove solvent (a) and thereby obtain the carrier material (b) in solid form with payload (c) dispersed therein as nanoparticles.

Description

Claims (11)

5. A process according toclaim 1, for making a nano-dispersion of a water insoluble material in a water-soluble carrier material comprising the steps of:
(i) providing a mixture of:
a) an aqueous solvent for a carrier material;
b) at least one water-soluble carrier material soluble in the mixture of aqueous solvent (a) and second solvent (c), said carrier material being solid at ambient temperature,
c) at least one non-aqueous second solvent said second solvent being miscible with aqueous solvent (a) to form a mixed solvent capable of dissolving carrier material (b) and payload (d), and;
d) a payload material which is dispersible or soluble in the mixture of aqueous solvent (a) and non-aqueous solvent (c) but not in aqueous solvent (a) alone, and;
(ii) drying the mixture at above ambient temperature to remove solvents (a) and (c) and thereby obtain the carrier material (b) in a solid form with payload (d) dispersed therein in a nanoparticulate form, wherein the product of the drying step is water dispersible to give an aqueous solution of (b) and an aqueous nano dispersion of (d).
6. A process according toclaim 1, for making water-soluble nano-dispersions of water insoluble materials in a water-soluble carrier material comprising the steps of:
(i) providing a mixture of:
a) a non-aqueous solvent or a mixture of miscible non-aqueous solvents,
b) at least one carrier material soluble in non-aqueous solvent (a), said carrier material being also soluble in water and solid at ambient temperature,
c) at least one water-insoluble payload material which is soluble in non-aqueous solvent (a), and,
(ii) drying the mixture above ambient temperature to remove solvent (a) and thereby obtain the carrier material (b) in solid form with payload material (c) dispersed therein in a nanoparticulate form, wherein the product of the drying step is water dispersible to give an aqueous solution of (b) and an aqueous nano dispersion of (c).
US12/309,3062006-07-132007-06-29NanodispersionsAbandonedUS20090175953A1 (en)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
GBGB0613925.7AGB0613925D0 (en)2006-07-132006-07-13Improvements relating to nanodispersions
GB0613925.72006-07-13
PCT/EP2007/056560WO2008006712A2 (en)2006-07-132007-06-29Preparation of nanodispersions

Publications (1)

Publication NumberPublication Date
US20090175953A1true US20090175953A1 (en)2009-07-09

Family

ID=36955583

Family Applications (10)

Application NumberTitlePriority DateFiling Date
US12/309,293AbandonedUS20090239749A1 (en)2006-07-132007-06-29Biocidal compositions
US12/309,294Active2028-07-27US8821932B2 (en)2006-07-132007-06-29Pharmaceutical compositions
US12/309,295AbandonedUS20100015233A1 (en)2006-07-132007-06-29anti-parasitic compositions
US12/309,306AbandonedUS20090175953A1 (en)2006-07-132007-06-29Nanodispersions
US12/309,292Active2030-01-29US9060937B2 (en)2006-07-132007-06-29Pharmaceutical compositions
US12/309,343AbandonedUS20100008995A1 (en)2006-07-132007-07-13Processes for preparing pharmaceutical compositions
US12/309,341Expired - Fee RelatedUS7691873B2 (en)2006-07-132007-07-13Preparation of pharmaceutical formulations
US12/309,344Expired - Fee RelatedUS8945626B2 (en)2006-07-132007-07-13Preparation of pharmaceutical compositions
US13/365,830AbandonedUS20120135058A1 (en)2006-07-132012-02-03Nanodispersions
US13/365,826AbandonedUS20120134940A1 (en)2006-07-132012-02-03Nanodispersions

Family Applications Before (3)

Application NumberTitlePriority DateFiling Date
US12/309,293AbandonedUS20090239749A1 (en)2006-07-132007-06-29Biocidal compositions
US12/309,294Active2028-07-27US8821932B2 (en)2006-07-132007-06-29Pharmaceutical compositions
US12/309,295AbandonedUS20100015233A1 (en)2006-07-132007-06-29anti-parasitic compositions

Family Applications After (6)

Application NumberTitlePriority DateFiling Date
US12/309,292Active2030-01-29US9060937B2 (en)2006-07-132007-06-29Pharmaceutical compositions
US12/309,343AbandonedUS20100008995A1 (en)2006-07-132007-07-13Processes for preparing pharmaceutical compositions
US12/309,341Expired - Fee RelatedUS7691873B2 (en)2006-07-132007-07-13Preparation of pharmaceutical formulations
US12/309,344Expired - Fee RelatedUS8945626B2 (en)2006-07-132007-07-13Preparation of pharmaceutical compositions
US13/365,830AbandonedUS20120135058A1 (en)2006-07-132012-02-03Nanodispersions
US13/365,826AbandonedUS20120134940A1 (en)2006-07-132012-02-03Nanodispersions

Country Status (17)

CountryLink
US (10)US20090239749A1 (en)
EP (8)EP2040678A2 (en)
JP (9)JP2009542760A (en)
CN (11)CN101489531A (en)
AP (1)AP2008004713A0 (en)
AR (4)AR061991A1 (en)
AU (9)AU2007271830B2 (en)
BR (8)BRPI0714179A2 (en)
CA (8)CA2656217A1 (en)
CL (4)CL2007002030A1 (en)
ES (2)ES2752460T3 (en)
GB (1)GB0613925D0 (en)
IL (2)IL195911A0 (en)
MX (2)MX2009000309A (en)
TW (1)TW200812694A (en)
WO (8)WO2008006713A2 (en)
ZA (7)ZA200900029B (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20080262100A1 (en)*2005-01-282008-10-23Andrew Ian CooperMethod of Preparing Carrier Liquids
WO2012082765A2 (en)2010-12-162012-06-21The United State Of America. As Represented By The Secretary Department Of Health And Human ServicesMethods for decreasing body weight and treating diabetes
WO2012142160A1 (en)2011-04-122012-10-18Rigel Pharmaceuticals, Inc.Methods for inhibiting allograft rejection
WO2015061361A1 (en)2013-10-212015-04-30Salk Institute For Biological StudiesMutated fibroblast growth factor (fgf) 1 and methods of use
WO2015134920A1 (en)2014-03-072015-09-11The Arizona Board Of Regents On Behalf Of The University Of ArizonaNon-narcotic crmp2 peptides targeting sodium channels for chronic pain
WO2018160772A1 (en)2017-02-282018-09-07The United State Of America, As Represented By The Secretary, Department Of Health & Human ServicesMethod of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis
CN108601342A (en)*2016-02-022018-09-28赢创德固赛有限公司Powdered formulation, its production method and its purposes with surface reactive material on solid, water soluble carrier
WO2020072805A1 (en)2018-10-042020-04-09Rutgers, The State University Of New JerseyMethods of reducing type 2 cytokine-mediated inflammation using neuromedin peptides
WO2020186187A1 (en)2019-03-132020-09-17University Of Pittsburgh - Of The Commonwealth System Of Higher EducationMethods for treating bladder and urethra dysfunction and disease
WO2021062012A1 (en)2019-09-252021-04-01Emory UniversityUse of klk10 and engineered derivatizations thereof
WO2021146625A1 (en)2020-01-172021-07-22The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesGene therapy for treatment of crx-autosomal dominant retinopathies
WO2021225781A2 (en)2020-05-072021-11-11The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesAberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
WO2023196898A1 (en)2022-04-072023-10-12The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesBeta globin mimetic peptides and their use
WO2024196814A1 (en)2023-03-172024-09-26The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesMethods for treatment of age-related macular degeneration

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2007133758A1 (en)*2006-05-152007-11-22Physical Pharmaceutica, LlcComposition and improved method for preparation of small particles
GB0613925D0 (en)*2006-07-132006-08-23Unilever PlcImprovements relating to nanodispersions
WO2008022651A1 (en)2006-08-212008-02-28Antoine TurziProcess and device for the preparation of platelet rich plasma for extemporaneous use and combination thereof with skin and bone cells
AR063704A1 (en)2006-09-142009-02-11Makhteshim Chem Works Ltd PESTICIDE NANOPARTICLES OBTAINED OBTAINED FROM MICROEMULSIONS AND NANOEMULSIONS
SI2124556T1 (en)2006-10-092015-01-30Charleston Laboratories, Inc.Pharmaceutical compositions
WO2009081283A2 (en)*2007-06-182009-07-02Combino Pharm, S.L.Aqueous formulations of acetaminophen for injection
EP2170313A2 (en)*2007-06-182010-04-07Combino Pharm, S.L.Aqueous formulations of acetaminophen for injection
US9254268B2 (en)2007-09-252016-02-09Solubest Ltd.Compositions comprising lipophilic active compounds and method for their preparation
CA3066426A1 (en)2008-01-092009-07-16Charleston Laboratories, Inc.Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
TR200800634A2 (en)*2008-01-302009-02-23Takka Sevgi̇ Fluvastatin tablet for extended release.
CN102105136B (en)*2008-03-112014-11-26蒂宝制药公司Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en)*2008-03-112013-02-12Depomed, Inc.Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US20110117157A1 (en)*2008-07-112011-05-19Nippon Soda Co., Ltd.Method of manufacture of sustained-release formulation composition
GB0814953D0 (en)*2008-08-182008-09-24Unilever PlcImprovements relating to nanodisperse compositions
CN105309424B (en)2008-09-252022-09-02维乌作物保护有限公司Method for producing polymer nanoparticles and preparation of active ingredients
FR2938433B1 (en)*2008-11-192011-09-09Francois Fauran PHARMACEUTICAL COMPOSITIONS USING INULIN AS A GRANULATING EXCIPIENT
WO2010082840A1 (en)*2008-12-122010-07-22Tim Tech Chemicals LimitedCompositions for the treatment of timber and other wood substrates
EP2243477A1 (en)2009-04-222010-10-27Fresenius Kabi Deutschland GmbHParacetamol for parenteral application
JP2012527491A (en)*2009-05-272012-11-08サムヤン バイオファーマシューティカルズ コーポレイション Slightly soluble drug-containing microspheres with improved bioavailability and method for producing the same
HUP0900384A2 (en)*2009-06-192011-01-28Nangenex Nanotechnologiai Zartkoerueen Muekoedoe ReszvenytarsasagNanoparticulate olmesartan medoxomil compositions
HUP0900376A2 (en)*2009-06-192011-01-28Nangenex Nanotechnologiai Zartkoerueen Muekoedoe ReszvenytarsasagNanoparticulate candesartan cilexetil composition
CN102802611B (en)*2009-06-252014-11-12进洋制药株式会社Pharmaceutical composition containing carboxylosartan and a production method therefor
CA2767576C (en)2009-07-082020-03-10Charleston Laboratories Inc.Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
RU2012112552A (en)*2009-08-312013-10-10Дипомед, Инк. PHARMACEUTICAL COMPOSITIONS REMAINED IN THE STOMACH FOR IMMEDIATE AND LONG RELEASE OF ACETAMINOPHENE
JP5498769B2 (en)*2009-12-042014-05-21花王株式会社 Method for producing lipid-soluble drug-encapsulating nanoparticles
US9198861B2 (en)2009-12-222015-12-01Mallinckrodt LlcMethods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en)2009-12-222013-12-03Mallinckrodt LlcMethods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
WO2011102702A2 (en)2010-02-162011-08-25Krka, D. D., Novo MestoProcess for the preparation of oral solid dosage forms comprising valsartan
US20130028976A1 (en)2010-03-292013-01-31Firmenich SaSpray-dried crystalline active ingredient
GB201006038D0 (en)2010-04-122010-05-26Unilever PlcImprovements relating to antiviral compositions
UA111167C2 (en)*2010-08-052016-04-11ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі PESTICIDIC COMPOSITIONS OF MECHANIZED PARTICLES WITH STRENGTH
JP2014500782A (en)*2010-10-052014-01-16イオタ・ナノソリューションズ・リミテッド Process for preparing an improved composition
US8877221B2 (en)2010-10-272014-11-04Warsaw Orthopedic, Inc.Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en)2010-10-272015-08-18Warsaw Orthopedic, Inc.Osteoconductive matrices comprising statins
US8741885B1 (en)2011-05-172014-06-03Mallinckrodt LlcGastric retentive extended release pharmaceutical compositions
US8658631B1 (en)2011-05-172014-02-25Mallinckrodt LlcCombination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en)2011-05-172014-10-14Mallinckrodt LlcTamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
WO2012170417A2 (en)2011-06-062012-12-13Warsaw Orthopedic, Inc.Methods and compositions to enhance bone growth comprising a statin
JP2013001771A (en)*2011-06-142013-01-07Neos Co LtdLiquid mold control detergent composition
RU2469536C1 (en)*2011-06-162012-12-20Государственное бюджетное учреждение Республики Башкортостан "Научно-исследовательский технологический институт гербицидов и регуляторов роста растений с опытно-экспериментальным производством Академии наук Республики Башкортостан"Fungicidal agent and method of its production
AU2012272804B2 (en)2011-06-222017-07-06Vyome Therapeutics LimitedConjugate-based antifungal and antibacterial prodrugs
MX373228B (en)2011-08-232020-04-21Vive Crop Prot Inc PYRETHROID FORMULATIONS.
GB201115079D0 (en)*2011-08-312011-10-19Iota Nanosolutions LtdMethod of preparing carrier liquids
GB201115634D0 (en)2011-09-092011-10-26Univ LiverpoolCompositions of lopinavir
GB201115633D0 (en)2011-09-092011-10-26Univ LiverpoolCompositions of efavirenz
GB201115635D0 (en)2011-09-092011-10-26Univ LiverpoolCompositions of lopinavir and ritonavir
US8609684B2 (en)*2011-12-122013-12-17PruGen IP Holdings, Inc.Solubilization and bioavailability of acetaminophen
WO2013093578A1 (en)2011-12-222013-06-27Vive Crop Protection Inc.Strobilurin formulations
JP6247685B2 (en)*2012-05-162017-12-13メワ・シン Pharmaceutical composition for delivery of substantially water-insoluble drugs
ES2698611T3 (en)2012-07-122019-02-05SpecGx LLC Pharmaceutical compositions dissuasive of abuse and prolonged release
US20140073678A1 (en)*2012-09-122014-03-13Monosol Rx, LlcAnti-pain and anti-nausea and/or vomiting combinatorial compositions
JP2016523232A (en)2013-06-042016-08-08ビョーメ バイオサイエンシズ ピーブイティー.リミテッド Coated particles and compositions containing same
CA2919892C (en)2013-08-122019-06-18Pharmaceutical Manufacturing Research Services, Inc.Extruded immediate release abuse deterrent pill
EP3069733B1 (en)*2013-11-132022-08-10National Defense Education and Research FoundationNew acetaminophen compound composition without side effect to liver
WO2015095391A1 (en)2013-12-172015-06-25Pharmaceutical Manufacturing Research Services, Inc.Extruded extended release abuse deterrent pill
US9492444B2 (en)2013-12-172016-11-15Pharmaceutical Manufacturing Research Services, Inc.Extruded extended release abuse deterrent pill
EP2952208A1 (en)*2014-06-042015-12-09Universidade de Santiago de CompostelaHydroalcoholic system for nail treatment
WO2015191282A1 (en)2014-06-112015-12-17Mallinckrodt LlcSpray dried compositions having different dissolution profiles and processes for their preparation
CN104042626A (en)*2014-07-012014-09-17李绍明Bactericidal and bacteriostatic agent
DK3169315T3 (en)2014-07-172020-08-10Pharmaceutical Manufacturing Res Services In Liquid-filled dosage form to prevent immediate release abuse
JP2017531026A (en)2014-10-202017-10-19ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド Sustained release abuse deterrent liquid filler form
US10315330B2 (en)*2014-12-232019-06-11Dow Global Technologies LlcTreated porous material
JP6730315B2 (en)*2015-01-202020-07-29メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Solid dispersion of compounds using polyvinyl alcohol as carrier polymer
CN104798772B (en)*2015-03-132017-05-24中国农业科学院农业环境与可持续发展研究所Pesticide nano-solid dispersion and preparation method thereof
MX2017016423A (en)2015-07-022018-12-11Civitas Therapeutics IncTriptan powders for pulmonary delivery.
ES2952606T3 (en)2015-07-172023-11-02Univ Oklahoma Licophelone derivatives and methods of use
CN105145553A (en)*2015-10-122015-12-16广西田园生化股份有限公司Indissolvable pesticide solid dispersion composition
US10179109B2 (en)2016-03-042019-01-15Charleston Laboratories, Inc.Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
WO2017216564A1 (en)2016-06-162017-12-21The University Of LiverpoolChemical composition
RU2619249C1 (en)*2016-11-072017-05-12Федеральное государственное бюджетное учреждение науки Институт химии твердого тела и механохимии Сибирского отделения Российской академии наук (ИХТТМ СО РАН)Composition for seed treatment and method of its production
JP2020515607A (en)2017-03-312020-05-28ザ ユニバーシティー オブ リヴァプール Prodrug composition
JP6960475B2 (en)*2017-06-152021-11-05サビオール ライフテック コーポレーションSavior Lifetec Corporation Manufacturing method of active ingredient particles
US11517013B2 (en)2017-08-252022-12-06Vive Crop Protection Inc.Multi-component, soil-applied, pesticidal compositions
EP3758683A1 (en)2018-03-022021-01-06The University Of LiverpoolSolid compositions of actives, processes for preparing same and uses of such solid compositions
JP6858729B2 (en)*2018-05-252021-04-14▲財▼▲団▼法人国防教育研究基金会National Defense Education And Research Foundation New acetaminophen complex composition with no side effects on the liver
CN113260257B (en)*2018-12-282022-09-06南京善思生物科技有限公司Nano pesticide preparation and preparation method thereof
CN109846821B (en)*2019-01-032021-07-06昆药集团股份有限公司Artemether nano preparation and preparation method thereof
CN110074993A (en)*2019-06-052019-08-02山东大学A method of preparing ultraviolet absorber nano particle
EP3990025A4 (en)*2019-06-282023-08-02Solstar Pharma GASTRIC RETENTION AND EXTENDED RELEASE FORMULATION AGAINST HELICOBACTER PYLORI
CN114615889A (en)*2019-10-282022-06-10组合化学工业株式会社Pesticide composition and method for producing same
IT202000022789A1 (en)2020-09-282020-12-28Vitop Moulding Srl Dispenser tap equipped with positioning, blocking and orientation system on Bag-In-Box type boxes
GB202115049D0 (en)2021-10-202021-12-01Univ LiverpoolChemical Compositions
CN114732009B (en)*2022-06-132022-08-23山东百农思达生物科技有限公司Preparation method of water dispersible granules containing pyraclostrobin and dimethomorph
GB202304657D0 (en)2023-03-292023-05-10Univ LiverpoolAtovaquine compositions

Citations (13)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4081529A (en)*1976-05-051978-03-28Inverni Della Beffa S.P.A.Polyhydroxyphenylchromanones
US5985248A (en)*1996-12-311999-11-16Inhale Therapeutic SystemsProcesses for spray drying solutions of hydrophobic drugs and compositions thereof
US20020041896A1 (en)*1999-05-272002-04-11Acusphere, Inc.Porous paclitaxel matrices and methods of manufacture thereof
US20030198674A1 (en)*2002-02-012003-10-23Curatolo William J.Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
US20040028505A1 (en)*2002-06-072004-02-12Bilbrey Robert A.Document tape binding system with automatic tape feed, tape indicia sensing, spine printing method and post-bind automation mechanisms
US20040064834A1 (en)*2001-08-212004-04-01Masayuki KuwataInformation processing system, information processing apparatus and method
US20040194338A1 (en)*2002-02-012004-10-07Pfizer IncMethod for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
US20040202669A1 (en)*2002-12-272004-10-14O'hagan DerekImmunogenic compositions containing phospholipid
US20040247624A1 (en)*2003-06-052004-12-09Unger Evan CharlesMethods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US6835396B2 (en)*2001-09-262004-12-28Baxter International Inc.Preparation of submicron sized nanoparticles via dispersion lyophilization
US20050014043A1 (en)*2003-07-182005-01-20Matsushita Electric Industrial Co., Ltd.Power supply unit
US20050163855A1 (en)*2004-01-272005-07-28Cj CorporationMethod of preparing low-crystallinity oltipraz or amorphous oltipraz
US20060003011A1 (en)*2001-06-222006-01-05Pfizer IncPharmaceutical compositions of drugs and neutralized acidic polymers

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
GB501835A (en)1936-05-291939-03-02Siemens AgProcess and apparatus for reducing the power required for the mechanical treatment of movable masses
GB1305024A (en)*1969-07-101973-01-31
US4230687A (en)*1978-05-301980-10-28Griffith Laboratories U.S.A., Inc.Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices
DE3439482A1 (en)*1984-10-271986-05-07Röhm GmbH, 6100 Darmstadt METHOD FOR COATING SUBSTRATES WITH SCRATCH-RESISTANT, NON-REFLECTIVE COVERS
US4830858A (en)*1985-02-111989-05-16E. R. Squibb & Sons, Inc.Spray-drying method for preparing liposomes and products produced thereby
US5160530A (en)*1989-01-241992-11-03Griffin CorporationMicroencapsulated polymorphic agriculturally active material
GB8918807D0 (en)*1989-08-171989-09-27Shell Int ResearchA solid pesticidal formulation,a process for its preparation and the use thereof
JP3067810B2 (en)*1990-12-212000-07-24中外製薬株式会社 Method for producing dry powder of O / W emulsion for oral administration
GB9304294D0 (en)*1993-03-031993-04-21Zeneca LtdHerbicidal compositions
DE4329446A1 (en)*1993-09-011995-03-02Basf Ag Process for the production of finely divided color or active substance preparations
US5858398A (en)*1994-11-031999-01-12Isomed Inc.Microparticular pharmaceutical compositions
TW318777B (en)*1995-06-291997-11-01Novartis Ag
WO1997013503A1 (en)*1995-10-131997-04-17The Penn State Research FoundationSynthesis of drug nanoparticles by spray drying
GB9606188D0 (en)1996-03-231996-05-29Danbiosyst UkPollysaccharide microspheres for the pulmonary delivery of drugs
US5858409A (en)1996-04-171999-01-12Fmc CorporationHydrolyzed cellulose granulations for pharmaceuticals
JP4183279B2 (en)*1997-04-152008-11-19アール ピー シェーラー テクノロジーズ インコーポレーテッド Hydrolyzed cellulose granules for pharmaceutical use
KR20010041623A (en)*1998-03-052001-05-25니뽄 신야쿠 가부시키가이샤Fat emulsions for inhalational administration
JPH11322587A (en)1998-05-181999-11-24Sumitomo Chem Co Ltd Method for microencapsulating a physiologically active substance solid at room temperature and microcapsule composition obtained by this method
EP1058539A1 (en)*1999-01-062000-12-13Korea Research Institute Of Chemical TechnologyMethod of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same
ES2307482T3 (en)*1999-02-102008-12-01Pfizer Products Inc. SOLID PHARMACEUTICAL DISPERSIONS.
GB9904012D0 (en)1999-02-221999-04-14Zeneca LtdAgrochemical formulation
EP1180020B2 (en)*1999-05-272009-06-24Acusphere, Inc.Porous drug matrices and methods of manufacture thereof
US7919119B2 (en)*1999-05-272011-04-05Acusphere, Inc.Porous drug matrices and methods of manufacture thereof
US6395300B1 (en)1999-05-272002-05-28Acusphere, Inc.Porous drug matrices and methods of manufacture thereof
GB9915231D0 (en)1999-06-291999-09-01Pfizer LtdPharmaceutical complex
GB9920148D0 (en)*1999-08-251999-10-27Smithkline Beecham PlcNovel composition
EP1246668B1 (en)*1999-12-012005-11-30Natco Pharma LimitedAn rapid acting freeze dired oral pharmaceutical composition for treating migraine
KR100694667B1 (en)*1999-12-082007-03-14동아제약주식회사 Itraconazole-containing antifungal agents that improve bioavailability and reduce absorption variation between and in individuals
US6207674B1 (en)1999-12-222001-03-27Richard A. SmithDextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
AU7488001A (en)2000-05-222001-12-03Verion IncMethod for increasing the compressibility of poorly binding powder materials
US6932963B2 (en)*2000-06-232005-08-23Nicholas V. PerriconeTreatment of skin wounds using polyenylphosphatidylcholine and alkanolamines
IT1318618B1 (en)2000-07-102003-08-27A C R Applied Coating Res S A QUICK RELEASE BIOADHESIVE MICROSPHERES FOR SUBLINGUAL ADMINISTRATION OF ACTIVE INGREDIENTS.
JP5070670B2 (en)*2000-07-242012-11-14小野薬品工業株式会社 N- [o- (p-pivaloyloxybenzenesulfonylamino) benzoyl] glycine monosodium salt tetrahydrate freeze-dried preparation and method for producing the same
DE10036871A1 (en)*2000-07-282002-02-14Pharmasol Gmbh Dispersions for the formulation of poorly or poorly soluble active ingredients
WO2002024169A1 (en)*2000-09-202002-03-28Skyepharma Canada Inc.Spray drying process and compositions of fenofibrate
US6756062B2 (en)*2000-11-032004-06-29Board Of Regents University Of Texas SystemPreparation of drug particles using evaporation precipitation into aqueous solutions
US8067032B2 (en)*2000-12-222011-11-29Baxter International Inc.Method for preparing submicron particles of antineoplastic agents
AU2002243760A1 (en)*2001-01-302002-08-12Board Of Regents University Of Texas SystemProcess for production of nanoparticles and microparticles by spray freezing into liquid
US6355675B1 (en)2001-05-152002-03-12Isp Investments Inc.Emulsifiable concentrate of a water-insoluble fungicide
ATE474559T1 (en)*2001-06-012010-08-15Pozen Inc PHARMACEUTICAL COMPOSITIONS FOR COORDINATED DELIVERY OF NSAIDS
KR100425226B1 (en)*2001-07-032004-03-30주식회사 팜트리Compositions and preparation methods for bioavailable oral aceclofenac dosage forms
JP2005504090A (en)*2001-09-262005-02-10バクスター・インターナショナル・インコーポレイテッド Preparation of submicron size-nanoparticles by removal of dispersion and solvent or liquid phase
DE10151392A1 (en)*2001-10-182003-05-08Bayer Cropscience Ag Powdery solid formulations
JP4235109B2 (en)*2001-11-072009-03-11ビーエーエスエフ ソシエタス・ヨーロピア Crop protection solid formulation containing sinidone-ethyl and corresponding dispersion
EP1465485B1 (en)*2001-11-072006-04-26Basf AktiengesellschaftNanoparticles comprising a crop protection agent
US6780324B2 (en)*2002-03-182004-08-24Labopharm, Inc.Preparation of sterile stabilized nanodispersions
WO2003103640A1 (en)2002-06-102003-12-18Elan Pharma International, LtdNanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (“statins”), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
US20030017208A1 (en)*2002-07-192003-01-23Francis IgnatiousElectrospun pharmaceutical compositions
DE10244681A1 (en)*2002-09-242004-04-08Boehringer Ingelheim International Gmbh New solid telmisartan-containing pharmaceutical formulations and their preparation
US20040105778A1 (en)*2002-10-042004-06-03Elan Pharma International LimitedGamma irradiation of solid nanoparticulate active agents
CN1176649C (en)2002-10-162004-11-24上海医药工业研究院 Sumatriptan dry powder inhalation and preparation method thereof
WO2004098570A1 (en)*2002-10-302004-11-18Spherics, Inc.Nanoparticulate bioactive agents
DK1575566T3 (en)*2002-12-262012-03-26Pozen Inc Multilayer dosage forms containing naproxen and triptans
US20060210620A1 (en)2003-01-212006-09-21Kumra Pannanchukunnath MCo-precipitated amorphous losartan and dosage forms comprising the same
US20040197301A1 (en)*2003-02-182004-10-07Zhong ZhaoHybrid polymers and methods of making the same
CA2514875A1 (en)*2003-02-192004-09-02Biovail Laboratories International SrlRapid absorption selective 5-ht agonist formulations
WO2004075921A1 (en)*2003-02-262004-09-10Vrije Universiteit BrusselInclusion complex of artemisinin or derivates thereof with cyclodextrins
US20040259899A1 (en)2003-04-082004-12-23Sanghvi Suketu P.Combination therapy for constipation
CA2465565A1 (en)2003-06-122004-12-12Warner-Lambert Company LlcPharmaceutical compositions of atorvastatin
EP1648515B1 (en)2003-07-162012-11-21Boehringer Ingelheim International GmbHChlorthalidone combinations
CL2004001884A1 (en)2003-08-042005-06-03Pfizer Prod Inc DRYING PROCEDURE FOR SPRAYING FOR THE FORMATION OF SOLID DISPERSIONS AMORPHES OF A PHARMACO AND POLYMERS.
DE10338403A1 (en)*2003-08-182005-03-17Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder formulation containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1 H) -oxoquinazolin-3-yl] -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyrindinyl) piperazine, process for its preparation and its use as inhalant
DE10351004A1 (en)*2003-10-302005-05-25Basf AgAqueous nanodispersion-forming formulations of active agents, especially plant protectants such as fungicides, comprise random copolymer of unsaturated sulfonic acid(s)
DE10351087A1 (en)*2003-10-312005-05-25Bayer Technology Services Gmbh Solid active ingredient formulation
KR100603974B1 (en)*2003-12-052006-07-25김갑식Method for preparing nano-scale or amorphous particle using solid fat as a solvent
EP1701703B1 (en)*2003-12-312011-03-09Bend Research, Inc.Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers and stabilizing polymers
IL160095A0 (en)*2004-01-282004-06-20Yissum Res Dev CoFormulations for poorly soluble drugs
JP2005298347A (en)*2004-04-062005-10-27Yoshiaki KawashimaInhalation preparation and method for producing the same
KR100598326B1 (en)*2004-04-102006-07-10한미약품 주식회사 Sustained-release preparations for oral administration of a HMVII-COA reductase inhibitor and preparation method thereof
CN1946302A (en)*2004-04-282007-04-11荷兰联合利华有限公司Edible oil containing statins
WO2005117834A1 (en)*2004-05-272005-12-15Janssen Pharmaceutica N.V.Solid dispersions of a basic drug compound and a polymer containing acidic groups
ES2339682T3 (en)2004-06-012010-05-24Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag PROCEDURE FOR THE PREPARATION OF THE AMORPHY FORM OF A PHARMACO.
DE102004031298A1 (en)2004-06-282006-01-12Basf Ag Aqueous dispersions of poorly water-soluble or water-insoluble active ingredients and dry powders prepared therefrom containing at least one polymer containing polyether groups as protective colloid
EP1806129A1 (en)*2004-10-012007-07-11Eisai R&D Management Co., Ltd.Composition containing fine particles and process for producing the same
US20060105038A1 (en)*2004-11-122006-05-18Eurand Pharmaceuticals LimitedTaste-masked pharmaceutical compositions prepared by coacervation
EP1835890A2 (en)*2005-01-062007-09-26Elan Pharma International LimitedNanoparticulate candesartan formulations
GB0501835D0 (en)*2005-01-282005-03-09Unilever PlcImprovements relating to spray dried compositions
GB0613925D0 (en)*2006-07-132006-08-23Unilever PlcImprovements relating to nanodispersions
US20080152717A1 (en)*2006-12-142008-06-26Isp Investments, Inc.Amorphous valsartan and the production thereof

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4081529A (en)*1976-05-051978-03-28Inverni Della Beffa S.P.A.Polyhydroxyphenylchromanones
US5985248A (en)*1996-12-311999-11-16Inhale Therapeutic SystemsProcesses for spray drying solutions of hydrophobic drugs and compositions thereof
US20020041896A1 (en)*1999-05-272002-04-11Acusphere, Inc.Porous paclitaxel matrices and methods of manufacture thereof
US20060003011A1 (en)*2001-06-222006-01-05Pfizer IncPharmaceutical compositions of drugs and neutralized acidic polymers
US20040064834A1 (en)*2001-08-212004-04-01Masayuki KuwataInformation processing system, information processing apparatus and method
US6835396B2 (en)*2001-09-262004-12-28Baxter International Inc.Preparation of submicron sized nanoparticles via dispersion lyophilization
US20030198674A1 (en)*2002-02-012003-10-23Curatolo William J.Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
US20040194338A1 (en)*2002-02-012004-10-07Pfizer IncMethod for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
US20040028505A1 (en)*2002-06-072004-02-12Bilbrey Robert A.Document tape binding system with automatic tape feed, tape indicia sensing, spine printing method and post-bind automation mechanisms
US20040202669A1 (en)*2002-12-272004-10-14O'hagan DerekImmunogenic compositions containing phospholipid
US20040247624A1 (en)*2003-06-052004-12-09Unger Evan CharlesMethods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US20050014043A1 (en)*2003-07-182005-01-20Matsushita Electric Industrial Co., Ltd.Power supply unit
US20050163855A1 (en)*2004-01-272005-07-28Cj CorporationMethod of preparing low-crystallinity oltipraz or amorphous oltipraz

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SX Yin, M Franchini, J Chen, A Hsieh, S Jen, T Lee, M Hussain, R Smith. "Bioavailability Enhancement of a COX-2 Inhibitor, BMS-347070, from a Nanocrystalline Dispersion Prepared by Spray-Drying." Journal of Pharmaceutical Sciences, Vol. 94, No. 7, July 2005, pages 1598-1607.*

Cited By (15)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20080262100A1 (en)*2005-01-282008-10-23Andrew Ian CooperMethod of Preparing Carrier Liquids
WO2012082765A2 (en)2010-12-162012-06-21The United State Of America. As Represented By The Secretary Department Of Health And Human ServicesMethods for decreasing body weight and treating diabetes
WO2012142160A1 (en)2011-04-122012-10-18Rigel Pharmaceuticals, Inc.Methods for inhibiting allograft rejection
WO2015061361A1 (en)2013-10-212015-04-30Salk Institute For Biological StudiesMutated fibroblast growth factor (fgf) 1 and methods of use
WO2015134920A1 (en)2014-03-072015-09-11The Arizona Board Of Regents On Behalf Of The University Of ArizonaNon-narcotic crmp2 peptides targeting sodium channels for chronic pain
CN108601342A (en)*2016-02-022018-09-28赢创德固赛有限公司Powdered formulation, its production method and its purposes with surface reactive material on solid, water soluble carrier
US20190037838A1 (en)*2016-02-022019-02-07Evonik Degussa GmbhPowdery formulations with surface active substances on solid, water-soluble carriers, method for the production and use thereof
WO2018160772A1 (en)2017-02-282018-09-07The United State Of America, As Represented By The Secretary, Department Of Health & Human ServicesMethod of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis
WO2020072805A1 (en)2018-10-042020-04-09Rutgers, The State University Of New JerseyMethods of reducing type 2 cytokine-mediated inflammation using neuromedin peptides
WO2020186187A1 (en)2019-03-132020-09-17University Of Pittsburgh - Of The Commonwealth System Of Higher EducationMethods for treating bladder and urethra dysfunction and disease
WO2021062012A1 (en)2019-09-252021-04-01Emory UniversityUse of klk10 and engineered derivatizations thereof
WO2021146625A1 (en)2020-01-172021-07-22The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesGene therapy for treatment of crx-autosomal dominant retinopathies
WO2021225781A2 (en)2020-05-072021-11-11The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesAberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
WO2023196898A1 (en)2022-04-072023-10-12The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesBeta globin mimetic peptides and their use
WO2024196814A1 (en)2023-03-172024-09-26The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesMethods for treatment of age-related macular degeneration

Also Published As

Publication numberPublication date
BRPI0714177A2 (en)2011-05-03
WO2008006713A3 (en)2008-07-31
AR061990A1 (en)2008-08-10
BRPI0714230A2 (en)2013-01-15
CL2007002030A1 (en)2008-01-18
ZA200900030B (en)2010-04-28
AU2007271828A1 (en)2008-01-17
CN101489532A (en)2009-07-22
CA2656223A1 (en)2008-01-17
AU2007271830A1 (en)2008-01-17
WO2008006715A3 (en)2008-05-08
CN102671585A (en)2012-09-19
ZA200900345B (en)2010-05-26
US20090239749A1 (en)2009-09-24
WO2008006716A3 (en)2008-03-13
MX2009000307A (en)2009-01-26
CL2007002032A1 (en)2008-01-18
CA2659666A1 (en)2008-01-17
JP2009542762A (en)2009-12-03
AU2007274040A1 (en)2008-01-17
CL2007002031A1 (en)2008-01-18
WO2008006714A2 (en)2008-01-17
CA2656233A1 (en)2008-01-17
IL195933A (en)2013-06-27
CN101489531A (en)2009-07-22
EP2386292A1 (en)2011-11-16
CN101516341A (en)2009-08-26
WO2008007150A1 (en)2008-01-17
WO2008007152A3 (en)2008-03-06
CN101516340A (en)2009-08-26
CL2010000516A1 (en)2010-10-15
AU2007271831B2 (en)2010-11-18
WO2008007151A2 (en)2008-01-17
BRPI0714179A2 (en)2012-12-25
MX2009000309A (en)2009-01-26
CN101489535A (en)2009-07-22
WO2008006712A2 (en)2008-01-17
WO2008007151A3 (en)2008-03-06
BRPI0714353A2 (en)2013-05-07
EP2040678A2 (en)2009-04-01
EP2040681B1 (en)2017-08-09
WO2008006714A3 (en)2008-02-21
US20090304806A1 (en)2009-12-10
CA2657582A1 (en)2008-01-17
AU2007271827B2 (en)2010-10-14
CA2656217A1 (en)2008-01-17
CN101849911A (en)2010-10-06
AU2007271827A1 (en)2008-01-17
WO2008007152A2 (en)2008-01-17
US7691873B2 (en)2010-04-06
ZA200900031B (en)2010-04-28
EP2269581A1 (en)2011-01-05
IL195911A0 (en)2009-09-01
ZA200900347B (en)2010-04-28
ES2741124T3 (en)2020-02-10
AR061992A1 (en)2008-08-10
US9060937B2 (en)2015-06-23
US20100068282A1 (en)2010-03-18
AU2007271828B2 (en)2010-12-02
AR061991A1 (en)2008-08-10
BRPI0714351A2 (en)2013-03-19
CN102631874A (en)2012-08-15
ZA200900027B (en)2010-04-28
US8945626B2 (en)2015-02-03
CN101489533A (en)2009-07-22
EP2387992A1 (en)2011-11-23
CA2656229A1 (en)2008-01-17
WO2008006713A2 (en)2008-01-17
WO2008006715A2 (en)2008-01-17
GB0613925D0 (en)2006-08-23
ES2752460T3 (en)2020-04-06
EP2040677A2 (en)2009-04-01
US20090325995A1 (en)2009-12-31
EP2040680A2 (en)2009-04-01
EP2040677B1 (en)2019-05-08
AU2007271830B2 (en)2010-11-11
US20120135058A1 (en)2012-05-31
EP2040681A2 (en)2009-04-01
WO2008006716A2 (en)2008-01-17
JP2009542760A (en)2009-12-03
JP2009542794A (en)2009-12-03
ZA200900029B (en)2010-04-28
AR077195A2 (en)2011-08-10
AU2007271829A1 (en)2008-01-17
CN101489534A (en)2009-07-22
EP2040679A2 (en)2009-04-01
BRPI0714176A2 (en)2012-12-25
CA2657586A1 (en)2008-01-17
AP2008004713A0 (en)2008-12-31
JP2010202665A (en)2010-09-16
AU2007274041A1 (en)2008-01-17
AU2010201900A1 (en)2010-06-03
US20100015229A1 (en)2010-01-21
BRPI0714352A2 (en)2013-03-19
WO2008006712A3 (en)2009-02-26
US20120134940A1 (en)2012-05-31
TW200812694A (en)2008-03-16
JP2009542761A (en)2009-12-03
CA2656229C (en)2014-05-27
US20100015233A1 (en)2010-01-21
EP2040680B1 (en)2019-08-07
CA2657548A1 (en)2008-01-17
BRPI0722376A2 (en)2012-05-22
JP2009542793A (en)2009-12-03
AU2007271829B2 (en)2011-10-27
AU2007274039A1 (en)2008-01-17
AU2007271831A1 (en)2008-01-17
CN101516342A (en)2009-08-26
JP2009542764A (en)2009-12-03
JP2009542763A (en)2009-12-03
IL195933A0 (en)2009-09-01
US8821932B2 (en)2014-09-02
ZA200900028B (en)2010-04-28
US20100008995A1 (en)2010-01-14
JP2009542795A (en)2009-12-03

Similar Documents

PublicationPublication DateTitle
US20090175953A1 (en)Nanodispersions
US20170112125A1 (en)Processes for preparing improved compositions
CA2601340C (en)Improvements relating to rapidly dissolving compositions
US20110217381A1 (en)Pharmaceutical compositions
US9718036B2 (en)Method of preparing carrier liquids

Legal Events

DateCodeTitleDescription
ASAssignment

Owner name:CONOPCO, INC. D/B/A UNILEVER, NEW JERSEY

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ANGUS, DORIS;DUNCALF, DAVID JOHN;ELPHICK, ANDREW JAMES;AND OTHERS;REEL/FRAME:022518/0499

Effective date:20070726

ASAssignment

Owner name:IOTA NANOSOLUTIONS LIMITED, UNITED KINGDOM

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONOPCO, INC. D/B/A UNILEVER;REEL/FRAME:025886/0872

Effective date:20110225

ASAssignment

Owner name:IOTA NANOSOLUTIONS LIMITED, UNITED KINGDOM

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONOPCO, INC. D/B/A UNILEVER;REEL/FRAME:026485/0862

Effective date:20110610

STCBInformation on status: application discontinuation

Free format text:ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION


[8]ページ先頭

©2009-2025 Movatter.jp